16 February 2024 – In 2023, Swissmedic, the Swiss Agency for Therapeutic Products, authorised 41 medicinal products with new active substances for the Swiss market.

The overview presents the indications, as well as the type and duration of the authorisation procedures. Swissmedic is also participating in two benchmarking studies aimed at comparing the authorisation times with those of the leading partner authorities. The results of these studies will be published during the course of 2024.

For more information, see here.